BioSpace News Archive

Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021.

Lantheus Holdings, Inc., an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Thursday, June 3.

Validant, a leading global quality, compliance and regulatory consulting group, has acquired Clinical Outcomes Solutions (“COS”), a global leader in clinical outcomes assessments (COA).

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 – June 8, 2021 and five abstracts at the virtual 26th Annual Congress of the European Hematology Association (EHA2021) from June 9 –16, 2021.

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2021 financial results after market close on Thursday, May 27, 2021.

Matinas will highlight progress across its lipid nanocrystal (LNC) delivery platform and associated pipeline programs

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021

ImmunoPrecise Moves SARS-CoV-2 PolyTope ™ Cocktail Program’s Path Toward IND Filing - Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment - Dr. Ilse Roodink and Dr. Debby Kruijsen to host live webinar “Function First: Using complementary antibody platforms to fight Covid-19” today at 11:00 am Eastern Daylight Time

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries

NeuPath Health Inc., owner and operator of a network of clinics that deliver category-leading treatment for chronic pain, as well as spinal injuries, sports-related injuries, and concussions, announced its financial and operating results for the three months ended March 31, 2021.